F atty acids are the predominant fuel used by the adult heart under aerobic conditions, 1,2 providing ATP via mitochondrial β-oxidation and oxidative phosphorylation. During ischemia, cardiac metabolism must rapidly adapt to the limited oxygen supply, to optimize anaerobic ATP generation in order to ensure cell survival. Ischemia upregulates glucose uptake and glycogenolysis, which increases glycolysis and oxygenindependent ATP generation, accompanied by downregulation of mitochondrial fatty acid oxidation and pyruvate oxidation. 3, 4 These acute metabolic changes are facilitated by rapid changes in enzyme activity and protein localization, and changes may persist during the early reperfusion phase, having a subsequent effect once the oxygen supply is reinstated. 5 It is important to understand the metabolic changes that occur during ischemia and reperfusion, as these influence the metabolic phenotype that may subsequently develop postreperfusion.
are located at different positions in relation to the sarcolemma: FABPpm is associated with the sarcolemmal extracellular surface, FAT/CD36 lies within the transmembrane region, and FATP1 is associated with the sarcolemmal intracellular surface. Similar to the glucose transporters relocating to regulate glucose uptake, fatty acid transporters can move to the sarcolemma to modify the rate of fatty acid uptake acutely. FAT/CD36 is hypothesized to be the key regulated step in this process, 11 translocating to the sarcolemma to increase fatty acid uptake in response to insulin, contraction, and AMP-activated protein kinase (AMPK) activation. [12] [13] [14] Reverse translocation away from the sarcolemma, to decrease fatty acid uptake, has received far less attention and has not been demonstrated in response to acute physiological stimuli. During ischemia, GLUT4 translocates to the sarcolemma to increase glucose uptake via an AMPK-dependent mechanism. 7, 15 However, movement of the fatty acid transporters in response to cardiac ischemia has not been investigated, and their relationship to fatty acid metabolism during reperfusion has not been studied.
We hypothesized that acute movement of fatty acid transporters away from the sarcolemma during ischemia would contribute to decreased fatty acid metabolism, in an attempt to match fatty acid uptake to fatty acid utilization and prevent lipid accumulation. Therefore, we investigated the effect of ischemia and reperfusion on fatty acid and glucose transporter subcellular localization and the downstream effects on glucose and fatty acid utilization and storage in the isolated perfused heart. In addition, we used metabolomic profiling to identify changes in metabolic intermediates, which may accumulate or become depleted due to changes in flux through their respective metabolic pathways during cardiac ischemia and reperfusion.
Methods

Isolated Heart Perfusion
Male Wistar rats (n=50; 291±5 g) were obtained from a commercial breeder (Harlan, United Kingdom). All procedures were in accordance with Home Office (United Kingdom) guidelines under The Animals (Scientific Procedures) Act, 1986, following approval by the Institutional Review Board and in accordance with institutional guidelines. Following terminal anesthesia with sodium pentobarbital, hearts were rapidly excised and placed in ice-cold Krebs-Henseleit (KH) buffer. Hearts were cannulated via the aorta and perfused in Langendorff mode at a constant perfusion pressure of 100 mm Hg at 37°C. Hearts were perfused with 200 mL recirculating KH buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 , 1.3 mM CaCl 2 , 0.5 mM EDTA, 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 ; pH 7.4) containing 11 mM glucose and 0.4 mM palmitate (bound to 1.5% fatty acid-free bovine serum albumin), gassed with 95% O 2 and 5% CO 2 . 16 To measure functional changes during the perfusion protocol, a fluid-filled PVC balloon was inserted into the left ventricle, inflated to achieve an end-diastolic pressure of 4 mm Hg, and attached via a polyethylene tube to a bridge amplifier and PowerLab data acquisition system (ADInstruments, Oxfordshire, United Kingdom). Left ventricular developed pressure was determined as systolic pressure minus end-diastolic pressure. Rate pressure product (RPP) was calculated as the product of developed pressure and heart rate.
Perfusion Protocol
Hearts were initially perfused under aerobic conditions for 30 minutes, termed preischemia, with typical flow rates of 16 mL/min per gram wet weight (gww). 16 Hearts subsequently underwent 30 minutes of low-flow ischemia at a constant flow rate of 0.4 mL/min/gww, followed by 30 minutes of aerobic reperfusion under conditions identical to preischemia. Hearts were perfused with 3 H-labeled substrates for measurement of metabolic rates throughout preischemia, ischemia, and reperfusion. A separate group of hearts was perfused without radiolabel and were freeze-clamped on the cannula using Wollenberger clamps prechilled in liquid nitrogen, at the end of preischemia, at the end of ischemia, or at the end of reperfusion.
Measurement of Metabolic Rates
For measurement of palmitate oxidation rates, 0.2 µCi/mL [9,10-3 H]palmitate was bound to albumin in the recirculating KH buffer. For measurement of glycolytic rates, a separate group of hearts was perfused with KH buffer supplemented with 0.2 μCi/mL 1 [5-3 H]glucose. 17 Timed aliquots of perfusate were collected during the perfusion protocol. Palmitate oxidation rates were determined from the conversion of 3 H-palmitate to 3 H 2 O, and glycolytic rates were determined from the conversion of 3 H-glucose to 3 H 2 O in the timed aliquots. 18 Lactate efflux was measured in aliquots using lactate dehydrogenase, as described. 19 Steady-state metabolic rates were calculated from the linear increase in 3 H 2 O or lactate.
Metabolomics
Metabolites from cardiac tissue were extracted using a methanol/ chloroform/water extraction procedure. 20 Tissue was pulverized in methanol/chloroform (2:1, v/v) solution; water and chloroform were added; the resulting aqueous and organic layers were separated and the organic layer was dried. Aqueous samples were derivatized using the procedure reported by Gullberg et al. 21 Methoxyamine hydrochloride (20 mg/mL in pyridine) was added to a quarter of the total aqueous fraction. The samples were derivatized at room temperature for 17 hours, followed by silylation with 30 µL of N-methyl-Ntrimethylsilyltrifluoroacetamide for 1 hour. The derivatized samples were diluted (1:10) with hexane prior to gas chromatography-mass spectrometry (GC/MS) analysis. One quarter of the total organicphase metabolites were derivatized by acid-catalyzed esterification. 22 Lipids were dissolved in chloroform/methanol (1:1, v/v). An aliquot of BF3/methanol was added and the vials were incubated at 80°C for 90 minutes. Once cool, 0.3 mL H 2 O and 0.6 mL hexane were added to each vial, and the organic layer was isolated and evaporated to dryness before reconstitution in 1 mL hexane for analysis.
The derivatized aqueous samples were injected into a Thermo Electron Trace GC Ultra equipped with a 30 m×0.25 mm ID 5% phenyl polysilphenylene-siloxane column with a chemically bonded 25 mm TR-5MS stationary phase (Thermo Electron Corporation; injector temperature 220°C, helium carrier gas flow rate 1.2 mL/min). The initial column temperature was 70°C, which was held for 2 minutes, then increased by 5°C/min up to a temperature of 230°C, and then increased at a rate of 20°C/min to 310°C. The derivatized organic metabolites were injected onto a ZB-WAX column (30 m×0.25 mm ID; 100% polyethylene glycol). The initial column temperature was 60°C; this was held for 2 minutes and then increased by 10°C/min to 150°C and then by 4°C/min up to a temperature of 230°C where it was held for 7 minutes. The column eluent was introduced into a DSQ quadrupole mass spectrometer (Thermo Electron Corporation; transfer line temperature 310°C for aqueous metabolites and 230°C for lipid metabolites, ion source temperature 250°C, electron beam 70 eV). The detector was turned on after a solvent delay of 240 seconds and data were collected in full-scan mode using 3 scans per second across a mass range of 50 to 650 m/z. Data were normalized to internal standard or total integral area, corrected for tissue weight, and expressed relative to the preischemic control group. In total, 75 metabolites were identified and analyzed (see Tables I and II in the online-only Data Supplement for the list of aqueous metabolites).
For specific analysis of diacylglycerols, chloroform:methanol lipid extracts were further diluted in isopropanol:acetonitrile:water (2:1:1) containing 20 μM C17 phosphatidylcholine. Mass spectra were collected in positive and negative mode using a Xevo QToF mass spectrometer interfaced with an ultra performance liquid chromatography unit. Spectra were acquired from 50 to 1200 m/z with a capillary voltage and cone voltage of 3.0 kV and 30 V for positive ion mode and 2.5 kV and 25 V for negative ion mode, respectively. Lipids were separated using a CSH C18 column, with mobile phases consisting of A (10 mM ammonium formate in 3:2 acetonitile:water) and B (10 mM ammonium formate in 9:1 isopropanol:acetonitrile). Lipid species were identified by MS/MS and reference to online databases. Data were imported into SIMCA software for processing using multivariate statistics, including principal components analysis, partial least squares discriminate analysis, and orthogonal partial least squares discriminate analysis. Diacylglycerides were identified by a combination of retention time and mass matching, with a data set created from features detected between 9 to 11 minutes retention time and 568.51 to 650.53 amu.
Subcellular Fractionation
Separation of the sarcolemmal membrane fraction from intracellular endosomes (low-density microsomal fraction) was carried out according to the established method of Luiken et al. 13 Briefly, cardiac tissue was incubated in a high-salt solution (20 mM HEPES, 2 mol/L NaCl, and 5 mM NaN 3 ), followed by centrifugation, resuspension in fractionation buffer (20 mM HEPES, 250 mM sucrose, 2 mM EDTA, 1 mM MgCl 2 , 5 mM NaN 3 ), and homogenization in a glass hand-held homogenizer. Differential centrifugation was used to separate the membrane fractions, and as described previously, sarcolemmal fractions had 3-fold enrichment of Na + K + -ATPase protein levels, whereas microsomal fractions had 9-fold enrichment of Rab4 protein levels. 19 
Tissue Analysis
The glycogen content of cardiac tissue was determined by the breakdown of glycogen to glucose units, using amyloglucosidase. Glycogenolysis and glycogenesis rates were calculated by taking the difference in glycogen content at the end of each time period and dividing by the time between samples. 23 The active fraction of pyruvate dehydrogenase was assayed according to the protocol of Seymour et al. 24 Myocardial triglyceride content was measured in crushed tissue, following Folch extraction, using a kit from Randox.
Western Blotting
Equal concentrations of protein were loaded and separated on 12.5% SDS-PAGE gels and transferred onto immobilon-p membranes (Millipore, United Kingdom). 16 FAT/CD36 was detected with an antibody kindly donated by Dr Narendra Tandon (Otsuka Maryland Medicinal Laboratories). FABPpm was detected using an antibody donated by Dr Jorge Calles-Escandon (Wake Forest University School of Medicine). Prof Geoff Holman (University of Bath, UK) donated the GLUT4 antibody. Antibodies against GLUT1 and FATP1 were purchased from Abcam and Santa Cruz, respectively. Antibodies raised against AMPK and phospho-AMPK (Thr172) were purchased from Cell Signaling. Even protein loading and transfer were confirmed by Ponceau staining, and protein levels were related to internal standards to ensure homogeneity between gels.
Statistical Analysis
Results are presented as means±SEM and were considered significant at P<0.05 (PASW Statistics 18). Metabolic rates and cardiac function were measured in the same heart under the 3 conditions and were analyzed using repeated measures general linear model with Bonferroni correction. All other data were from separate hearts collected at end of preischemia, end of ischemia, or end of reperfusion, and were analyzed using an unpaired one-way ANOVA with Tukey correction. Exact P values are given in Table III in the online-only Data Supplement.
Results
Cardiac Function
Cardiac function was stable throughout the 30-minute preischemic period of aerobic perfusion. During low-flow ischemia, left ventricular developed pressure and heart rate dropped to 16% and 10% of preischemic values, respectively, but recovered to preischemic levels during reperfusion (Table 1) . Despite the 98% decrease in RPP during ischemia, RPP returned to 86% of initial values during reperfusion. Thus, in agreement with previous studies, this perfusion protocol of 30 minutes of mild low-flow ischemia did not impair functional recovery of the heart; therefore, metabolic changes during reperfusion were unlikely to be due to decreased contractile function. 25 
Fatty Acid Metabolism
Fatty acids are the predominant substrate used by the heart to fuel contraction under aerobic conditions. 1,2 During ischemia, palmitate oxidation rates decreased by 95% compared with preischemic aerobic rates ( Figure 1 ). During reperfusion, palmitate oxidation rates fully recovered to preischemic rates, in line with contractile function. Fatty acids taken up by the cardiomyocyte can either be oxidized or stored; therefore, measurement of both pathways is necessary to give an indirect assessment of fatty acid uptake. 16, 26 The large decrease in fatty acid oxidation during ischemia was not accompanied by a change in myocardial triglyceride content. In contrast, the recovery of fatty acid oxidation during reperfusion was associated with a 35% decrease in myocardial triglyceride content. The total fatty acid pool in these hearts was assessed by GC/MS. There were no significant differences in the individual fatty acids or the fatty acid classes between preischemic, ischemic, and reperfused hearts ( Table 2) . Similarly, diacylglyerides were detected, but multivariate models revealed that no discrimination was achievable between the 3 perfusion conditions ( Figure I in the online-only Data Supplement). Thus, during ischemia, the decrease in fatty acid oxidation was not accompanied by an accumulation of myocardial lipids, suggesting that fatty acid uptake decreased in line with oxidation. In contrast, the full recovery of fatty acid oxidation rates during reperfusion occurred at the expense of the myocardial triglyceride stores, indicating that exogenous fatty acid uptake rates were not sufficient to fulfil oxidation rates in the reperfused heart.
Fatty Acid Transporters in Ischemia/Reperfusion
Fatty acid uptake can be acutely regulated by translocating fatty acid transporters between the sarcolemma and intracellular membrane compartments (endosomes). 13 During ischemia, sarcolemmal FAT/CD36 protein levels decreased by 32% compared with preischemia, due to movement of FAT/CD36 to the endosomes, as shown by the increase in FAT/CD36 in the microsomal fraction ( Figure 2 ). During reperfusion, this relocation away from the sarcolemma was maintained, with sarcolemmal FAT/CD36 content remaining significantly decreased compared with preischemia. In contract, the subcellular location of the other fatty acid transporters, FABPpm and FATP1, did not change following low-flow ischemia and reperfusion. There was no change in total FAT/CD36 protein levels under the different perfusion conditions ( Figure II in the online-only Data Supplement). Thus, this selective relocation of FAT/CD36 away from the sarcolemma would decrease the transporter-mediated capacity for fatty acid uptake, likely contributing to the changes in fatty acid metabolism during ischemia and reperfusion.
Glucose Transporters in Ischemia/Reperfusion
In contrast to the fatty acid transporters, movement of the glucose transporters showed the opposite profile ( Figure 3 ). Sarcolemmal GLUT4 content increased by 90% during ischemia, due to movement of the transporters away from the endosomal stores, as shown by the decrease in GLUT4 in the microsomal fraction. During reperfusion, GLUT4 remained significantly increased at the sarcolemma compared with preischemia. Changes in the sarcolemmal content of GLUT4 occurred independent of changes in total GLUT4 in the heart ( Figure II in the online-only Data Supplement). GLUT1 localization did not change in the isolated perfused hearts during 30 minutes of low-flow ischemia or subsequent reperfusion ( Figure 3 ).
Glucose Metabolism
Glycolytic rates under aerobic conditions were 0.27 μmol/ min per gram wet weight, which during low-flow ischemia increased by 86% compared with preischemic rates (Figure 4) . During reperfusion, glycolytic rates did not return to preischemic levels, but instead significantly decreased to only 30% of preischemic rates. Glycolytically derived pyruvate can be reduced to lactate, transaminated to alanine, or oxidized in the mitochondria by pyruvate dehydrogenase. During ischemia, net lactate efflux rates increased 3-fold compared with preischemic rates, and during reperfusion they decreased to significantly lower than preischemic levels, mirroring the changes in glycolytic rates. Intracellular lactate and alanine levels, as determined by metabolomic analysis of cardiac tissue, increased 7-fold and 4-fold, respectively, during ischemia. Pyruvate dehydrogenase activity did not change during ischemia, indicating that mitochondrial oxidation was not restricted at the level of pyruvate decarboxylation. However, pyruvate dehydrogenase activity was decreased by 63% in reperfused hearts compared with ischemic hearts, concomitant with the decrease in glycolysis and lactate efflux during reperfusion. Thus, GLUT4 translocation to the sarcolemma was associated with increased glycolysis during ischemia, but not during reperfusion.
Glycogen Metabolism
As glycolysis was decreased during reperfusion, despite the increased sarcolemmal GLUT4, we investigated whether glucose was being diverted into glycogen storage. Intracellular glucose levels decreased by 33% during ischemia and returned to preischemic levels during reperfusion, indicating that glucose uptake was maintained despite the decrease in glycolysis ( Figure 5 ). By the end of 30 minutes of low-flow ischemia, myocardial glycogen content had decreased by 45% compared with preischemia. The decrease of 4.15 μmol glucosyl units per gram wet weight during ischemia was equivalent to a net rate of glycogenolysis of 0.138 μmol/min per gram wet weight. 23 During 30 minutes of reperfusion, glycogen content increased 2-fold, back to preischemic levels, resulting in a net rate of glycogenesis of 0.17 μmol/min per gram wet weight. Thus, during reperfusion, the increased sarcolemmal GLUT4 content was associated with increased glycogenesis and replenishment of the glycogen stores.
Metabolic Intermediates and Regulation
Total protein levels of AMPK did not differ between groups ( Figure 5 ). However, phosphorylated AMPK was 3-fold higher in ischemic hearts, concomitant with the translocation of GLUT4 to the sarcolemma, increased glycolytic rates, and increased glycogenolysis. In contrast, after 30 minutes of reperfusion, phosphorylated AMPK returned to preischemic levels. Using metabolomic analysis, Krebs cycle intermediates were measured in cardiac tissue from the end of preischemia, low-flow ischemia, and reperfusion ( Figure 6 , and Tables I  and II in the online-only Data Supplement) . During ischemia, citrate levels decreased by 59% compared with preischemia. Succinate levels increased 5-fold during ischemia; however, levels of fumarate, the next metabolite in the cycle, malate, and cis-aconitate were unchanged. The accumulation of succinate relative to the unchanged subsequent metabolites indicated decreased flux through succinate dehydrogenase during ischemia. During reperfusion, citrate levels increased ≈2-fold compared with preischemia. Citrate is a potent inhibitor of phosphofructokinase activity and hence glycolysis; therefore, it likely contributed to the redirection of glucose away from glycolysis and toward glycogenesis at reperfusion. In addition, cis-aconitate levels were increased by 83% compared with preischemia, mirroring the changes in its precursor citrate. However, levels of succinate, fumarate, and malate were not significantly different following reperfusion. Citrate and cis-aconitate are metabolites prior to 2 dehydrogenase reactions (isocitrate and α-ketoglutarate dehydrogenase), and accumulation of these 2 metabolites relative to the unchanged subsequent metabolites indicates decreased flux through the Krebs cycle at the level of these enzymes. Thus, reduced flux through the dehydrogenase reactions would account for the increased citrate levels, the inhibition of glycolysis, and preferential replenishment of glycogen during reperfusion.
Discussion
We are the first to demonstrate FAT/CD36 relocation away from the sarcolemma, occurring in response to cardiac ischemia. In this study, we show that the ischemia-induced movement of FAT/CD36 away from the sarcolemma occurs concomitantly with the translocation of GLUT4 to the sarcolemma, demonstrating divergent regulation of these 2 transporters. The subcellular reorganization of substrate transporters in ischemia was associated with an acute shift from fatty acid oxidation to more oxygen-efficient glycolysis, in the absence of cellular lipid overload. During reperfusion, the decreased sarcolemmal FAT/CD36 was associated with depletion of triglycerides, as fatty acid oxidation rates were restored to preischemic levels. Concomitantly, the increased sarcolemmal GLUT4 facilitated the repletion of glycogen, associated with a citrate-mediated inhibition of glycolysis.
FAT/CD36 is the predominant regulatory site for fatty acid uptake, with strong positive relationships between sarcolemmal FAT/CD36 content and sarcolemmal fatty acid uptake rates. 27, 28 The relocation of FAT/CD36 away from the sarcolemma during ischemia and early reperfusion would be expected to decrease the rate of and capacity for fatty acid uptake directly and subsequently decrease fatty acid use by the heart. Nickerson et al 29 demonstrated that FAT/CD36 has far greater transporter efficiency than the other fatty acid transporters, and our findings in ischemia demonstrate a FAT/ CD36-specific relocation, with no movement of the other fatty acid transporters, FABPpm and FATP1, under the same conditions. Thus, the changes in sarcolemmal fatty acid uptake capacity in ischemia are likely a FAT/CD36-specific event.
The ischemia-induced near cessation of fatty acid oxidation was accompanied by only a 32% decrease in sarcolemmal FAT/CD36, which at first appearance seems a small change to be associated with such a large decrease in oxidation. However, in ischemia, there are 2 factors that have to be considered, not only the decrease in FAT/CD36, but also the cessation of contraction, the primary consumer of the fatty acid-derived ATP. Thus, in ischemia, it may be that the combined contribution of decreased sarcolemmal FAT/CD36 and decreased contraction would decrease overall fatty acid uptake. If considered in light of the reperfusion findings, in which contraction and fatty acid oxidation are normalized, whereas FAT/CD36 and triglycerides are reduced by 32% and 35%, respectively, these results may more closely elucidate the independent contribution of FAT/CD36 relocation to changes in fatty acid metabolism.
Decreased fatty acid oxidation during ischemia was not associated with a change in intramyocardial triglycerides or free fatty acids, indicating that fatty acid uptake likely decreased with ischemia. This is in line with a study showing decreased fatty acid uptake in an ischemic open chest swine model. 30 It has been proposed for many years that the primary destination of exogenous fatty acids following uptake is the myocardial triglyceride pool, that fatty acids transported from the circulation are first esterified into triglycerides, then hydrolyzed from this intermediary lipid pool for oxidation in the mitochondria when required. 31 This would explain our observations at reperfusion that, despite decreased sarcolemmal FAT/CD36, fatty acid oxidation rates were restored, occurring at the expense of intramyocardial triglycerides. Studies by Saddik et al, 32 using pulse-chase perfusion, showed that triglyceride lipolysis rates were not different between reperfusion and preischemia, and that rates of exogenous fatty acid oxidation also did not differ between the two. 32, 33 Therefore, at reperfusion, the decreased triglycerides were most likely due to decreased esterification of fatty acids into triglyceride, as a consequence of reduced FAT/ CD36-mediated uptake of fatty acids across the sarcolemma.
The mechanism underpinning the relocation of FAT/CD36 away from the sarcolemma is currently unknown. Whereas many signaling pathways have been shown to induce movement to the sarcolemma, to our best knowledge we are the first to show movement away. Forward transport to the sarcolemma and increased fatty acid uptake can be induced by AMPK, fatty acids, reactive oxygen species, insulin, and contraction 13, 14, 34, 35 ; therefore, these can all be ruled out as mediating our changes in ischemia, and contraction can be ruled out at reperfusion. The location of FAT/CD36 is determined by the balance between forward movement to, and reverse movement away from, the sarcolemma 36 ; thus it could be that either pathway is affected in ischemia. A potential mechanism that may explain our findings is related to pH changes during ischemia. Steinbusch et al 37 showed that increasing the pH in the endosomes induced translocation of FAT/CD36 to the sarcolemma; therefore, it is possible that the ischemia-induced decrease in pH due to lactate accumulation may decrease trafficking to the sarcolemma, resulting in an overall decrease in sarcolemmal FAT/CD36 content.
From a physiological point of view, having an ischemiainduced mechanism to restrict cytosolic fatty acid accumulation would be advantageous, as high intracellular concentrations of fatty acids decrease functional recovery of the ischemic heart during reperfusion. 38 Thus, the decrease in sarcolemmal FAT/CD36 likely occurs to limit fatty acid uptake under conditions in which there is insufficient oxygen available for oxidation, thereby protecting against lipid accumulation and contractile impairment. This would be even more significant in vivo, as the ischemia-induced catecholamine surge would induce adipose lipolysis and elevate plasma-free fatty acid concentrations, 39 thereby increasing the fatty acid concentration gradient across the sarcolemma.
During ischemia, the majority of glycolytic flux is from exogenous glucose, 40 facilitated by translocation of GLUT4 to the sarcolemma, 7 mediated by AMPK-dependent mechanisms. 15 This suggests that during ischemia not only are GLUT4 and FAT/CD36 travelling in different directions relative to the sarcolemma, but they are also regulated by different signaling pathways. The increased sarcolemmal GLUT4 ensured that sufficient intracellular substrate was available for ATP generation and was independent of a change in GLUT1 localization. Using pulse-chase experiments, Wambolt et al 40 demonstrated that glycogen-derived glycolytic rates accounted for 29% of the total glycolytic rate during low-flow ischemia, which was comparable with our 27% net rate of glycogenolysis in ischemic hearts. Glycogen turnover is regulated by the activity of both glycogen phosphorylase and glycogen synthase, with glycogen phosphorylase activity increasing during ischemia and glycogen synthase activity increasing during reperfusion. 23 Our findings of a net increase in glycogenesis during reperfusion provided evidence that during reperfusion, glucose uptake is not primarily for energy generation but for restoration of glycogen stores. 41, 42 It has been shown that if insufficient glycogen is available to fuel glycolysis during ischemia, then functional recovery of the heart is impaired, shortening the time to and increasing the severity of contracture. 43, 44 Thus, replenishing glycogen would be a priority for the heart during reperfusion, to optimize cell survival if a second ischemic period should follow.
Metabolomic analysis of ischemic and reperfused hearts allowed identification of multiple modified metabolites and indicated where flux through specific enzymes was modified. The ischemia-induced increase in glycolytic flux was likely mediated by 2 complimentary factors converging at the same enzyme: AMPK activation of phosphofructokinase 2 activity, 45 assisted by a decrease in citrate levels, a potent inhibitor of phosphofructokinase activity. 46 In contrast, during reperfusion the large increase in citrate would be expected to inhibit phosphofructokinase activity, accounting for the decrease in glycolysis and diversion of glucose-6-phosphate into the glycogen pool. Thus, changes in citrate levels are likely to be a key signal behind the catabolic to anabolic shift in glucose metabolism that occurs during reperfusion. Measuring the relative changes in Krebs cycle intermediates indicated changes in flux through specific enzymes and pointed toward reduced flux through succinate dehydrogenase during ischemia and through isocitrate and α-ketoglutarate dehydrogenase during reperfusion. These enzymes are key regulated steps in the Krebs cycle, with their activity influenced by the redox state of the mitochondria, and likely underpin the metabolic switch between pathways that occur during ischemia and reperfusion.
In conclusion, during ischemia, FAT/CD36 moved away as GLUT4 moved toward the sarcolemma, associated with a downregulation of fatty acid oxidation and an increase in glycolysis. During reperfusion, the substrate transporters remained in their ischemic location, which, in the case of GLUT4, was associated with replenishing glycogen stores at the expense of glycolysis, mediated by increased citrate levels. In contrast, restoration of fatty acid oxidation rates during reperfusion occurred despite decreased sarcolemmal FAT/ CD36, associated with depletion of triglyceride stores. Thus, sarcolemmal translocation of the fatty acid transporter FAT/ CD36 contributed to the acute cardiac metabolic remodelling that occurs during ischemia and reperfusion.
